Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

The Medicines Company’s PCSK9 Inhibitor for Cholesterol Looks Good in Phase III

The Medicines Company’s inclisiran hit the primary and secondary endpoints in a Phase III trial to decrease LDL cholesterol through twice-a-year dosing.

Read More »

Regeneron’s Evinacumab Effective in Treating Rare, Inherited High-Cholesterol Disease

Regeneron Pharmaceuticals announced positive results from the company’s pivotal Phase III clinical trial of evinacumab in homozygous familial hypercholesterolemia (HoFH).

Read More »

Amarin Plans to Double Size of Sales Force to 800

Amarin Corp. provided an update, noting that the company is increasing revenue guidance for 2019 and is planning to expand the sales force for Vascepa due to faster-than-expected growth.

Read More »

FDA approves expanded label for Praluent

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Read More »

Sanofi and Regeneron cutting list price of cholesterol drug by 60 percent

Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.

Read More »

New drug options, risk factors added to U.S. heart guidelines

Updated U.S. guidelines on heart health advise more personalized assessment of risk as well as two newer types of cholesterol-lowering drugs for people at particularly high risk of heart attack or stroke.

Read More »

Esperion’s Bemopedoic Acid Treatments Hit the Mark in Two Studies

Ann Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.

Read More »

Moderate ‘bad cholesterol’ levels tied to early death for healthy people

Healthy adults who do not keep their LDL-C, or “bad cholesterol,” in check are more likely to die prematurely from cardiovascular disease than peers with lower cholesterol levels, a U.S. study suggests.

Read More »

Esperion cholesterol drug succeeds in late-stage study

Esperion Therapeutics Inc. said a late-stage trial of the company’s experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.

Read More »

Almost any amount of exercise may help older men win longevity race

Older men may face a premature death if they spend most of the day sitting around, but it does not require a huge amount of exercise to increase their chances of living longer, a study in the UK suggests.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom